Champix Pfizer Europe MA EEIG · Authorised · authorised 25 Sep 2006 · ATC N07BA03
Therapeutic indication (EMA)
Champix is indicated for smoking cessation in adults.
Active substance
Varenicline
- SFDA 30
- US FDA 24
- EMA 1
- Health Canada 13
- US price lines 5
- NHS prices 4
- WHO EML 1
- Safety 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CHAMPIX 0.5 MG 11 tablets +1 MG 14 tablets | 0.5-1 mg | Film-coated tablet · Oral use | 25 Blister | SAR 133.40 | NCE · Prescription | Pfizer Europe MA EEIG | Valid |
| CHAMPIX 0.5 MG F-C TAB | 0.5 mg | Film-coated tablet · Oral use | 56 Blister | SAR 138.50 | NCE · Prescription | Pfizer Europe MA EEIG | Valid |
| CHAMPIX 1MG F-C TABLETS | 1 mg | Film-coated tablet · Oral use | 56 Blister | SAR 224.55 | NCE · Prescription | Pfizer Europe MA EEIG | Valid |
| CHAMPIX 1MG F-C TABLETS | 1 mg | Film-coated tablet · Oral use | 28 Blister | SAR 133.40 | NCE · Prescription | Pfizer Europe MA EEIG | Valid |
| Cigapix | 1 mg | Film-coated tablet · Oral use | 56 Blister | SAR 179.65 | Generic · Prescription | Saudi Amarox | Valid |
| Cigapix | 0.5 mg | Film-coated tablet · Oral use | 56 Blister | SAR 110.80 | Generic · Prescription | Saudi Amarox | Valid |
| Cimuquit | 0.5 & 1 mg | Film-coated tablet · Oral use | 25 Blister | SAR 115.60 | Generic · Prescription | BATTERJEE PHARMACETICAL FACTORY | Valid |
| Cimuquit | 0.5 mg | Film-coated tablet · Oral use | 56 Blister | SAR 120.00 | Generic · Prescription | BATTERJEE PHARMACETICAL FACTORY | Valid |
| Cimuquit | 1 mg | Film-coated tablet · Oral use | 56 Blister | SAR 194.60 | Generic · Prescription | BATTERJEE PHARMACETICAL FACTORY | Valid |
| Herocan | 0.5 mg | Film-coated tablet · Oral use | 56 Blister | SAR 110.80 | Generic · Prescription | APOTEX | Valid |
| Herocan | 1 mg | Film-coated tablet · Oral use | 56 Blister | SAR 179.65 | Generic · Prescription | APOTEX | Valid |
| Herocan | 1 mg | Film-coated tablet · Oral use | 28 Blister | SAR 106.70 | Generic · Prescription | APOTEX | Valid |
| Herocan | 1,0.5 mg,mg | Film-coated tablet · Oral use | 25 Blister | SAR 106.70 | Generic · Prescription | APOTEX | Valid |
| Herocan | 0.5 mg | Film-coated tablet · Oral use | 56 Bottle | SAR 110.80 | Generic · Prescription | APOTEX INC. (SIGNET SITE) | Valid |
| Herocan | 1 mg | Film-coated tablet · Oral use | 56 Bottle | SAR 179.65 | Generic · Prescription | APOTEX INC. (SIGNET SITE) | Valid |
| Herocan | 0.5 mg | Film-coated tablet · Oral use | 28 Blister | SAR 55.40 | Generic · Prescription | APOTEX INC. (SIGNET SITE) | Valid |
| Marvi | 0.5 mg | Film-coated tablet · Oral use | 14 Blister | SAR 30.00 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Marvi | 1 mg | Film-coated tablet · Oral use | 30 Blister | SAR 123.85 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Serna | 1,0.5 mg,mg | Film-coated tablet · Oral use | 25 Blister | SAR 106.70 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Serna | 1 mg | Film-coated tablet · Oral use | 56 Blister | SAR 179.65 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Serna | 1 mg | Film-coated tablet · Oral use | 28 Blister | SAR 106.70 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| VarNell | 0.5/1 mg | Film-coated tablet · Oral use | 25 Blister | SAR 106.70 | Generic · Prescription | Kinnova manufacturing company | Valid |
| VarNell | 1 mg | Film-coated tablet · Oral use | 56 Blister | SAR 179.65 | Generic · Prescription | Kinnova manufacturing company | Valid |
| Varenapix | 0.5 mg | Film-coated tablet · Oral use | 30 Blister | SAR 59.35 | Generic · Prescription | Spectro Pharma | Valid |
| Varenapix | 1 mg | Film-coated tablet · Oral use | 30 Blister | SAR 106.65 | Generic · Prescription | Spectro Pharma | Valid |
5 more — full table
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CHANTIX | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | PF PRISM CV | Prescription | 10 May 2006 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | PH HEALTH | Prescription | 11 Aug 2021 |
| TYRVAYA | EQ 0.03MG BASE/SPRAY | spray · nasal | OYSTER POINT PHARMA | Prescription | 15 Oct 2021 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | APOTEX | Prescription | 25 Jan 2023 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | ZYDUS | Prescription | 12 Jun 2023 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | KANCHAN HLTHCARE | Prescription | 25 Jul 2023 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | MANKIND PHARMA | Prescription | 1 Aug 2023 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | ALKEM LABS LTD | Prescription | 23 Aug 2023 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | HETERO LABS LTD III | Prescription | 23 Oct 2023 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | LUPIN | Prescription | 4 Dec 2023 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | NE RX PHARMA | Prescription | 6 Mar 2024 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | AJANTA PHARMA LTD | Prescription | 19 Mar 2024 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | PIRAMAL | Prescription | 23 Jul 2024 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | DR REDDYS | Prescription | 1 Oct 2024 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | REGCON HOLDINGS | Prescription | 29 Oct 2024 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | MACLEODS PHARMS | Prescription | 9 Dec 2024 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | ADAPTIS | Prescription | 8 Apr 2025 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | AUROBINDO PHARMA | Prescription | 2 May 2025 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | VIWIT PHARM | Prescription | 6 May 2025 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | MICRO LABS | Prescription | 29 Oct 2025 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | UMEDICA | Prescription | 9 Jan 2026 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | SOMERSET THERAPS LLC | Prescription | 6 Jul 2026 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | PHARMOBEDIENT | Discontinued | 29 Feb 2024 |
| VARENICLINE TARTRATE | EQ 0.5MG BASE; EQ 1MG BASE | tablet · oral | RHODES PHARMS | Discontinued | 21 May 2025 |
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-VARENICLINE | 02419882 | 0.5 MG | TABLET · ORAL | APOTEX INC |
| APO-VARENICLINE | 02419890 | 1 MG | TABLET · ORAL | APOTEX INC |
| APO-VARENICLINE | 02435675 | 0.5 MG; 1 MG | KIT; TABLET · ORAL | APOTEX INC |
| AURO-VARENICLINE | 02554445 | 0.5 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-VARENICLINE | 02554453 | 1 MG | TABLET · ORAL | AURO PHARMA INC |
| MINT-VARENICLINE | 02546949 | 0.5 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| MINT-VARENICLINE | 02546957 | 1 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| MINT-VARENICLINE | 02546965 | 0.5 MG; 1 MG | KIT; TABLET · ORAL | MINT PHARMACEUTICALS INC |
| NRA-VARENICLINE | 02542951 | 0.5 MG | TABLET · ORAL | NORA PHARMA INC |
| NRA-VARENICLINE | 02542978 | 1 MG | TABLET · ORAL | NORA PHARMA INC |
| NRA-VARENICLINE | 02542986 | 0.5 MG; 1 MG | TABLET; KIT · ORAL | NORA PHARMA INC |
| ZDS-VARENICLINE | 02559897 | 0.5 MG | TABLET · ORAL | ZYDUS LIFESCIENCES LIMITED |
| ZDS-VARENICLINE | 02559900 | 1 MG | TABLET · ORAL | ZYDUS LIFESCIENCES LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CHANTIX 1 MG CONT MONTH BOX | $3.40803 | per EA | 23 Sep 2026 |
| US NADAC | CHANTIX 1 MG TABLET | $3.40803 | per EA | 23 Sep 2026 |
| US NADAC | TYRVAYA 0.03 MG NASAL SPRAY | $79.62813 | per ML | 23 Sep 2026 |
| US NADAC | VARENICLINE 0.5 MG TABLET | $0.31158 | per EA | 23 Sep 2026 |
| US NADAC | VARENICLINE 1 MG TABLET | $0.3161 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Varenicline 1mg tablets | £18.16 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Varenicline 1mg tablets and Varenicline 500microgram tablets | £27.30 | 25 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Varenicline 1mg tablets and Varenicline 500microgram tablets | £40.95 | 53 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Varenicline 500microgram tablets | £54.60 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 24.5.2. Medicines for nicotine use disorders · core
Nicotine dependence
Oral > Solid: 0.5 mg; 1 mg
Safety signals and safety-related labeling changes
- US FDA 22 Feb 2019 CHANTIX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 14 Jun 2018 PRAC signal: Loss of consciousness
Action for MAH: update of the product information: Yes - EMA PRAC 8 Feb 2018 PRAC signal: Loss of consciousness
Action for MAH: update of the product information: No - EMA PRAC 5 Sep 2012 PRAC signal: Seizures
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.